Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

A new heterogeneous liver mass in a patient with well-controlled HIV and HBV infection.

Vogler MA.

AIDS Read. 2006 Aug;16(8):393-6, 401-2. No abstract available.

PMID:
16933373
2.

Compliance with hepatitis B and hepatitis C virus infection screening among HIV-1 infected patients in a resource-limited setting.

Sungkanuparph S, Wongprasit P, Manosuthi W, Atamasirikul K.

Southeast Asian J Trop Med Public Health. 2008 Sep;39(5):863-6.

PMID:
19058581
3.
4.

Characteristics and outcome of patients with dual hepatitis B and C-associated hepatocellular carcinoma: are they different from patients with single virus infection?

Huo TI, Huang YH, Hsia CY, Su CW, Lin HC, Hsu CY, Lee PC, Lui WY, Loong CC, Chiang JH, Chiou YY, Lee SD.

Liver Int. 2009 May;29(5):767-73. doi: 10.1111/j.1478-3231.2008.01908.x. Epub 2008 Nov 3.

PMID:
19018974
5.

Diagnosis and management of hepatitis B virus and HIV coinfection.

Peters MG.

Top HIV Med. 2007 Nov-Dec;15(5):163-6.

6.

Viable strategies to facilitate liver transplantation for human immunodeficiency virus coinfection.

Stock PG, Fung J.

Liver Transpl. 2009 Sep;15(9):1003-6. doi: 10.1002/lt.21840. No abstract available.

7.

Natural history of chronic hepatitis B - clinical implications.

McMahon BJ.

Medscape J Med. 2008 Apr 16;10(4):91. Review. No abstract available.

8.

[The significance of anti-HBc and occult hepatitis B virus infection in the occurrence of hepatocellular carcinoma in patients with HBsAg and anti-HCV negative alcoholic cirrhosis].

Kim MJ, Kwon OS, Chung NS, Lee SY, Jung HS, Park DK, Ku YS, Kim YK, Kim YS, Kim JH.

Korean J Hepatol. 2008 Mar;14(1):67-76. doi: 10.3350/kjhep.2008.14.1.67. Korean.

PMID:
18367859
9.

The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.

Murillas J, Rimola A, Laguno M, de Lazzari E, Rascón J, Agüero F, Blanco JL, Moitinho E, Moreno A, Miró JM; ESLD-HIV Working Group Investigators.

Liver Transpl. 2009 Sep;15(9):1133-41. doi: 10.1002/lt.21735.

10.

Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy.

Crane M, Oliver B, Matthews G, Avihingsanon A, Ubolyam S, Markovska V, Chang JJ, Dore GJ, Price P, Visvanathan K, French M, Ruxrungtham K, Lewin SR.

J Infect Dis. 2009 Apr 1;199(7):974-81. doi: 10.1086/597276.

PMID:
19231993
11.

Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study.

Fwu CW, Chien YC, Kirk GD, Nelson KE, You SL, Kuo HS, Feinleib M, Chen CJ.

J Natl Cancer Inst. 2009 Jul 15;101(14):1019-27. doi: 10.1093/jnci/djp146. Epub 2009 Jun 17.

PMID:
19535774
12.

Viral hepatitis and HIV-associated tuberculosis: risk factors and TB treatment outcomes in Thailand.

Sirinak C, Kittikraisak W, Pinjeesekikul D, Charusuntonsri P, Luanloed P, Srisuwanvilai LO, Nateniyom S, Akksilp S, Likanonsakul S, Sattayawuthipong W, Burapat C, Varma JK.

BMC Public Health. 2008 Jul 18;8:245. doi: 10.1186/1471-2458-8-245.

13.

Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.

Adachi S, Shibuya A, Miura Y, Takeuchi A, Nakazawa T, Saigenji K.

Scand J Gastroenterol. 2008;43(7):849-56. doi: 10.1080/00365520801935459.

PMID:
18584524
14.

Risk factors for acute liver enzyme abnormalities in HIV-hepatitis B virus-coinfected patients on antiretroviral therapy.

Chauvel O, Lacombe K, Bonnard P, Lascoux-Combe C, Molina JM, Miailhes P, Girard PM, Carrat F.

Antivir Ther. 2007;12(7):1115-26.

PMID:
18018770
15.

Characteristics and prognosis of patients in Japan with viral marker-negative hepatocellular carcinoma.

Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Kanamori A, Yamaguchi A, Isogai M, Kaneoka Y, Washizu J.

J Gastroenterol Hepatol. 2008 Mar;23(3):459-66. Epub 2007 Sep 14.

PMID:
17854425
16.

Hepatocellular carcinoma: the need for progress.

Thomas MB, Zhu AX.

J Clin Oncol. 2005 May 1;23(13):2892-9. Review. No abstract available.

PMID:
15860847
17.

Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection: clinically relevant or a diagnostic problem?

Rodríguez-Torres M, Gonzalez-Garcia J, Bräu N, Solá R, Moreno S, Rockstroh J, Smaill F, Mendes-Correa MC, DePamphilis J, Torriani FJ; APRICOT Investigators.

J Med Virol. 2007 Jun;79(6):694-700.

PMID:
17457912
18.

Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy.

Sheng WH, Kao JH, Chen PJ, Huang LM, Chang SY, Sun HY, Hung CC, Chen MY, Chang SC.

Clin Infect Dis. 2007 Nov 1;45(9):1221-9. Epub 2007 Sep 21.

PMID:
17918088
19.

Sclerosing haemangioma mimicking hepatocellular carcinoma.

Lee VT, Magnaye M, Tan HW, Thng CH, Ooi LL.

Singapore Med J. 2005 Mar;46(3):140-3.

20.

Supplemental Content

Support Center